SK Chemicals announces the world’s first commercialization approval of tetravalent cell-cultured influenza vaccine
On the 24th, SK Chemicals(CEO Man-hoon Park) announced acquisition of commercialization approval of ‘SKYCellflu Quadrivalent,’ a tetravalent cell-cultured influence vaccine, from the Ministry of Food and Drug Safety. It is the first time for a tetravalent cell-cultured influenza vaccine to be app...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
